XML 154 R7.htm IDEA: XBRL DOCUMENT v2.4.0.8
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
 9 Months Ended 12 Months Ended 201 Months Ended 210 Months Ended
Apr. 30, 2013
USD ($)
Apr. 30, 2012
USD ($)
Jul. 31, 2012
USD ($)
Jul. 31, 2011
USD ($)
Jul. 31, 2010
USD ($)
Jul. 31, 2012
USD ($)
Apr. 30, 2013
USD ($)
Cash Flows From Operating Activities:              
Net loss $ (4,999,736) $ (7,914,440) $ (9,490,278) $ (21,675,867) $ (25,279,940) $ (354,173,560) $ (359,173,296)
Adjustments to reconcile net loss to net cash used in operating activities:              
Depreciation and amortization 349,047 472,146 612,658 742,961 780,250 9,908,540 10,257,587
Minority interest share of loss 0 0 0 0 0 (3,038,185) (3,038,185)
Reduction of notes receivable - common stock in exchange for services rendered 0 0 0 0 0 423,882 423,882
Write-off of uncollectible notes receivable - common stock 0 0 0 0 0 391,103 391,103
Write-off of deferred offering costs 0 0 0 0 0 3,406,196 3,406,196
Write-off of abandoned patents 0 88,582 440,780 0 0 1,353,976 1,353,976
(Gain)/loss on disposal of property and equipment (1,036,865) (1,793,087) (2,027,939) 35,878 0 (1,991,150) (3,028,015)
Loss on extinguishment of debt 0 0 0 0 0 14,134,068 14,134,068
Common stock issued as employee compensation 0 68,483 130,544 100,999 101,002 4,011,938 4,011,938
Amortization of options and option modifications as stock compensation 613,375 56,961 602,384 936,465 1,765,381 3,411,226 4,024,601
Common stock issued for services rendered 223,692 606,545 699,445 1,990,005 1,755,200 14,507,279 14,730,971
Amortization of prepaid services in conjunction with common stock issuance 0 0 0 0 0 138,375 138,375
Non-cash compensation expense 0 0 0 0 0 45,390 45,390
Stock options and warrants issued for services rendered 0 0 0 0 591,000 7,956,723 7,956,723
Issuance of warrants as additional exercise right inducement 0 0 0 0 0 21,437,909 21,437,909
Preferred stock issued for services rendered 0 0 0 0 0 100 100
Treasury stock redeemed for non-performance of services 0 0 0 0 0 (138,000) (138,000)
Amortization of deferred debt issuance costs and loan origination fees 0 0 0 0 0 2,405,629 2,405,629
Amortization of discount on convertible debentures 0 0 0 0 0 38,345,592 38,345,592
Common stock issued for interest on convertible debentures & preferred stock 663,930 347,490 485,190 0 0 1,242,704 1,906,634
Interest on short-term advance 0 0 0 0 0 22,190 22,190
Founders' shares transferred for services rendered 0 0 0 0 0 353,506 353,506
Fees in connection with refinancing of debt 0 0 0 0 0 113,274 113,274
Warrant repricing costs 0 0 0 0 0 3,198,604 3,198,604
Change in fair value of derivative liabilities 1,092,504 1,603,720 1,081,440 (2,220,916) (4,125,590) 715,977 [1] 1,808,481 [2]
Changes in operating assets and liabilities (excluding the effects of acquisition):              
Accounts receivable 0 8,474 8,470 62,200 (12,482) (15,047) (15,047)
Miscellaneous receivables 0 0 0 0 0 43,812 43,812
Inventory 0 716,415 716,392 1,197,768 (618,401) (20,091) (20,091)
Other current assets 154,586 (70,693) 20,946 116,171 601,115 (182,948) (28,362)
Accounts payable and accrued expenses 212,595 (1,267,420) (1,218,616) 1,811,120 1,878,296 15,023,940 15,236,535
Deferred revenue (33,504) (81,634) (105,395) (28,152) 252,042 257,332 223,828
Other, net 0 0 0 0 0 110,317 110,317
Net Cash Used in Operating Activities (2,760,376) (7,158,458) (8,043,979) (16,931,368) (22,312,127) (216,599,398) (219,359,774)
Cash Flows From Investing Activities:              
Purchase of property and equipment 0 (2,416) (2,416) (52,383) (159,708) (4,809,439) (4,809,439)
Proceeds from sale of property and equipment 1,762,954 4,614,057 4,953,325 0 0 4,953,325 6,716,279
Costs incurred for patents (51,717) (110,929) (173,775) (234,984) (228,777) (2,840,046) (2,891,763)
Change in restricted cash 0 0 0 0 0 512,539 512,539
Proceeds from maturity of short term investments 0 0 0 0 0 195,242,918 195,242,918
Purchases of short-term investments 0 0 0 0 0 (195,242,918) (195,242,918)
Cash received in conjunction with merger 0 0 0 0 0 82,232 82,232
Advances to Antigen Express, Inc. 0 0 0 0 0 (32,000) (32,000)
Increase in officers' loans receivable 0 0 0 0 0 (1,126,157) (1,126,157)
Change in deposits 0 0 0 0 0 (652,071) (652,071)
Change in notes receivable - common stock 0 0 0 0 0 (91,103) (91,103)
Change in due from related parties 0 0 0 0 0 (2,222,390) (2,222,390)
Other, net 0 0 0 0 0 89,683 89,683
Net Cash Provided By (Used in) Investing Activities 1,711,237 4,500,712 4,777,134 (287,367) (388,485) (6,135,427) (4,424,190)
Cash Flows From Financing Activities:              
Proceeds from short-term advance 0 0 0 0 0 325,179 325,179
Repayment of short-term advance 0 0 0 0 0 (347,369) (347,369)
Proceeds from issuance of long-term debt 828,543 3,566,088 3,561,688 0 0 5,567,297 6,395,840
Repayment of long-term debt (1,832,170) (4,488,539) (4,821,511) (116,632) (100,030) (7,062,699) (8,894,869)
Repayment of obligations under capital lease 0 0 0 (7,818) (39,950) (83,002) (83,002)
Change in due to related parties 0 0 0 0 0 154,541 154,541
Proceeds from exercise of warrants 780,704 30,000 30,000 0 1,574,062 45,728,281 46,508,985
Proceeds from exercise of stock options 1,057 0 1,300 577 0 5,003,793 5,004,850
Proceeds from minority interest investment 0 0 0 0 0 3,038,185 3,038,185
Proceeds from issuance of preferred stock 1,450,000 1,975,000 1,975,000 2,315,000 0 16,305,000 17,755,000
Redemption of SVR preferred stock 0 0 0 0 0 (100) (100)
Proceeds from issuance of convertible debentures, net 0 0 0 0 0 40,704,930 40,704,930
Payment of costs associated with convertible debentures 0 0 0 0 0 (722,750) (722,750)
Repayments of convertible debentures 0 0 0 0 0 (5,142,424) (5,142,424)
Purchase of treasury stock 0 0 0 0 0 (483,869) (483,869)
Proceeds from issuance of common stock, net 0 0 0 3,939,000 20,900,289 120,576,242 120,576,242
Purchase and retirement of common stock 0 0 0 0 0 (497,522) (497,522)
Net Cash Provided by Financing Activities 1,228,134 1,082,549 746,477 6,130,127 22,334,371 223,063,713 224,291,847
Effect of Exchange Rates on Cash (18,723) (29,022) (32,120) 6,535 50,063 (82,579) (101,302)
Net (Decrease) Increase in Cash and Cash Equivalents 160,272 (1,604,219) (2,552,488) (11,082,073) (316,178) 246,309 406,581
Cash and Cash Equivalents, Beginning of Period 246,309 2,798,797 2,798,797 13,880,870 14,197,048 0 0
Cash and Cash Equivalents, End of Period $ 406,581 $ 1,194,578 $ 246,309 $ 2,798,797 $ 13,880,870 $ 246,309 $ 406,581
[1] includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to July 31, 2012" column. See Note 12 - Derivative Liabilities.
[2] Includes $5,981,403 as adjustment related to the adoption of FASB ASC Topic 815 in "Cumulative from November 2, 1995 (Date of Inception) to April 30, 2013" column. See Note 11 - Derivative Warrant Liability.